Day: June 13, 2024

Posted on

From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments

WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) — Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer.

Fatty liver disease is now estimated to affect 1 in 3 adults worldwide, and its prevalence is increasing. Fatty liver disease during childhood, once unheard of, is also on the rise. Early detection and timely intervention, whether through lifestyle changes or medical treatments, are essential in stopping and even reversing the progression of the disease. “Act Now, Screen Today” emphasizes that liver health is achievable, but action must begin immediately. Across the globe, partners are driving awareness and educational efforts and ensuring broader access to essential screenings and care.

Global Fatty Liver Day, observed annually on the second Thursday of June, is a rallying cry for collective action to address the growing prevalence of fatty liver disease, the most common liver disease worldwide. “Act Now, Screen Today” reminds everyone that liver health is within reach. Here are specific actions you can take today:

  • Take advantage of liver health screening events happening globally to get assessed for fatty liver disease or schedule a check-up with your doctor, especially if you are managing closely associated metabolic conditions like obesity or diabetes
  • Increase physical activity, as maintaining an active lifestyle can improve liver health
  • Learn about fatty liver disease and its risk factors to take proactive steps towards prevention and management yourself or learn more about the latest research and guidelines for your patients.

With a robust pipeline of pharmaceutical treatments that address diverse mechanisms of action in progress, it is important to identify individuals’ position within the progression of fatty liver disease so that they are poised to receive the most appropriate care possible. Notably, pharmaceutical treatments are available (for certain groups with advanced disease) in two countries, the United States (resmetirom) and India (saroglitazar).

“As a community, we stand at a critical time for the broader global health system to act now to support patients,” shares Donna R. Cryer, JD, Founder and CEO of GLI. “As pharmaceutical treatment options gain approval in different geographies, health payers and systems must listen to the call from global advocates and not place undue obstacles to care – whether that be required biopsy, ambiguous lifestyle requirements, or other hurdles – so that patients are able to access the care they require, no matter who or where they are.”

Recognizing the importance of early detection, a diverse range of partners, including healthcare providers, patient advocacy groups, and community organizations, have joined forces to “Act Now, Screen Today” and launch screening events around the world. From Chile to Nigeria to the Netherlands, the Philippines, and beyond, these events aim to raise awareness, provide education, and offer screening services to individuals at risk of fatty liver disease or the providers who care for them. Global Fatty Liver Day activities are driving positive change at the grassroots level.

“Global Fatty Liver Day is an urgent call-to-action to unite our global efforts to confront the scourge of fatty liver disease,” shares Cat Evans, Director of Program Operations at GLI. “We must act now. By working together, we have the power to create significant change in preventing and managing this pressing health issue through our collaborative efforts.”

Although the challenge of fatty liver disease to the well-being of communities around the globe is great, the power of locally-rooted, collective efforts can turn the tide towards positive change by heightening awareness, equipping people and their healthcare providers with prevention and management tools, expanding understanding of the disease through research, and protecting future liver health through effective policies.

About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube, or visit www.globalliver.org. GLI is the host of Global Fatty Liver Day.

Christine Maalouf
Global Liver Institute
cmaalouf@globalliver.org

GlobeNewswire Distribution ID 9153607

Posted on

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

ADALVO LIMITED
Anil Okay, Adalvo CEO, expresses his thoughts on this milestone

SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo’s capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo’s position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo’s Diabetes Portfolio

At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals – be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Adalvo’s dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, gabrielle.cassar@adalvo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966220

Posted on

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

ADALVO LIMITED
Anil Okay, Adalvo CEO, expresses his thoughts on this milestone

SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo’s capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo’s position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo’s Diabetes Portfolio

At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals – be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Adalvo’s dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, gabrielle.cassar@adalvo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966220

Posted on

Cashew Coast lève 9 millions d’euros auprès d’AgDevCo pour développer son activité de transformation de noix de cajou bio et traçable en Côte d’Ivoire

AgDevCo Ltd

Cashew Kernels from Ivory Coast Cashew Coast

LONDRES, 13 juin 2024 (GLOBE NEWSWIRE) — AgDevCo a le plaisir d’annoncer son dernier investissement en Côte d’Ivoire dans Cashew Coast, une entreprise de transformation de noix de cajou en pleine croissance, qui emploie 750 personnes et s’approvisionne localement auprès de plus de 7 000 agriculteurs.

La Côte d’Ivoire est le premier producteur de noix de cajou au monde. Ces noix sont cependant majoritairement exportées sous forme brute pour être transformées au Vietnam et en Inde, avant d’être expédiées vers les marchés finaux en Europe et aux États-Unis, un aller-retour long et coûteux.

Cashew Coast est le fer de lance d’une volonté nationale de retenir davantage de valeur dans l’économie Ivoirienne. En transformant localement et en exportant directement sa production vers les supermarchés et les utilisateurs d’ingrédients, l’entreprise peut payer des prix plus élevés aux agriculteurs qui lui fournissent des noix de cajou biologiques et entièrement traçables.

Avec un fort engagement social et environnemental, Cashew Coast a été le premier transformateur en Côte d’Ivoire à obtenir la certification BRCGS (norme mondiale de référence en matière de sécurité alimentaire). L’entreprise a également remporté le prestigieux prix Fairtrade Africa Award en 2023.

Le prêt mezzanine d’AgDevCo de 9,0 millions d’euros (5,9 milliards de FCFA) financera l’expansion de la capacité de transformation de l’entreprise et la construction de nouveaux entrepôts, ainsi que des programmes d’amélioration de la productivité des agriculteurs. L’investissement permettra de doubler les volumes transformés par l’entreprise pour atteindre 19 000 tonnes de noix de cajou par an.

« Transformer les noix de cajou à la source fait entièrement sens, tant d’un point de vue environnemental qu’économique. Nous sommes extrêmement ravis de commencer ce partenariat avec Cashew Coast qui soutiendra la croissance de l’entreprise, créera plus d’emplois dans les zones rurales et contribuera à faire de l’Afrique de l’Ouest un leader mondiale de la transformation de noix de cajou», a déclaré Ismail Sentissi, directeur des investissements d’AgDevCo pour l’Afrique de l’Ouest.

« Le financement flexible et de long terme apporté par AgDevCo, ainsi que leur expertise dans l’agro-industrie africaine et leur important réseau professionnel, sont autant d’éléments qui nous aideront à réaliser la vision de notre entreprise », a déclaré Salma Seetaroo, PDG et cofondatrice de Cashew Coast. «Nous sommes très heureux de conclure cet investissement et espérons que cette étape clé fera de Cashew Coast un modèle de réussite commerciale reproductible ailleurs en Afrique. »

AgDevCo est un investisseur spécialisé dans l’agro-industrie africaine. Avec 280 millions de dollars sous gestion, AgDevCo a pour ambition de contribuer à développer des entreprises durables et à fort impact sur le continent Africain, en créant des emplois, en produisant et en transformant localement, et en reliant les agriculteurs locaux au marchés finaux. AgDevCo a réalisé plus de 65 investissements à ce jour. Plus d’informations disponibles sur www.agdevco.com

Contact Details for media:

Ismail Sentissi, info@agdevco.com

GlobeNewswire Distribution ID 1000966158

Posted on

Cashew Coast raises €9 million from AgDevCo to expand its traceable organic cashew processing business in Cote d’Ivoire

AgDevCo Ltd

Cashew Kernels from Ivory Coast Cashew Coast

LONDON, June 13, 2024 (GLOBE NEWSWIRE) — Specialist agriculture investor AgDevCo is pleased to announce its latest investment in Cote d’Ivoire, into Cashew Coast, a fast-growing cashew nut processing business, which employs 750 people and sources from more than 7,000 smallholder farmers.

Cote d’Ivoire is the largest producer of cashew in the world. Most cashew nuts are still exported in raw form for processing in Vietnam and India, before being shipped to end markets in Europe and the USA, a lengthy and expensive round-trip.

Cashew Coast is in the vanguard of a drive to capture more value in the domestic industry. By processing the cashews at source and shipping directly to supermarkets and ingredient users, the company can pay higher prices to its farmers for fully traceable, organic cashew nuts.

With a commitment to the highest standards, Cashew Coast was the first processor in Cote d’Ivoire to achieve BRCGS certification (the leading global standard for food safety) for cashew kernel exports. It also won the prestigious Fairtrade Africa Award in 2023.

AgDevCo’s mezzanine loan of €9.0 million (5.9 billion FCFA) will finance the expansion of the company’s processing capacity and the construction of new warehouses, alongside farmer productivity programmes. The investment will double the company’s processed volumes to 19,000 tonnes of raw cashew nuts a year.

“On both commercial and sustainability grounds, it makes sense to process cashews at origin. We are delighted to begin this partnership with Cashew Coast which will support the company’s continued growth, create more jobs in rural areas and help build a globally competitive cashew processing industry in West Africa,” said Ismail Sentissi, AgDevCo’s Investment Director for West Africa.

“AgDevCo brings long-term, flexible capital, combined with agricultural acumen and a network of contacts that will help us achieve our ambitious goals,” said Salma Seetaroo, Cashew Coast’s CEO and co-founder. “We are very pleased to close this investment and hope this key milestone will entrench Cashew Coast as a successful and replicable African business model.”

AgDevCo is a specialist investor in African agriculture, growing sustainable and impactful agribusiness, with USD 280m under management. Their vision is a thriving commercial agriculture sector, which benefits both, people and planet, by investing in and supporting agribusinesses to grow, creating jobs, producing, and processing food and linking farmers to markets. They support their partners to work towards climate sustainability, and where possible, regenerative solutions. AgDevCo has made more than 65 investments to date. More information can be found at www.agdevco.com

Contact Details for media:

Ismail Sentissi, info@agdevco.com

GlobeNewswire Distribution ID 1000966158

Posted on

Nikkiso Clean Energy & Industrial Gases Group Announces CEO Transition July 1, 2024

TEMECULA, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Nikkiso Co., Ltd. (TSE: 6376), announced today after a Board vote, that effective July 1, 2024, Adrian Ridge will succeed Peter Wagner as Nikkiso Clean Energy & Industrial Gases Group’s (part of Nikkiso’s Industrial Division) as Chief Executive Officer. Wagner will stay on in a Board role as Executive Chairman for Nikkiso CE&IG Group.

As CEO, Ridge, who is currently Executive Vice President, Operations and Manufacturing for Nikkiso CE&IG Group, will drive operational and financial results and ready the Group for future growth. Wagner’s new role as Executive Chairman will focus on driving the vision and long-term strategy of the Group in an advisor capacity.

“In six years under Peter’s leadership, Nikkiso CE&IG has more than quadrupled business, and is positioned for strong continued growth,” said Toshihiko Kai, President and CEO, Nikkiso. “I want to thank him for his leadership, and welcome Adrian as the Group’s new CEO.”

Prior to joining Nikkiso in 2018, Wagner was CEO and Managing Director at LEWA Group. Ridge joined Nikkiso in 2022 after approximately 30 years at Atlas Copco serving in various leadership positions.

About Nikkiso Co. Ltd.

Since its establishment in 1953, Nikkiso has contributed to solving social issues by anticipating the changing times with world-first and Japan-first technologies and products. In the industrial business, Nikkiso has created new markets by developing products in the energy field, hemodialysis-related products in the medical business, and CFRP (carbon fiber reinforced plastic) aerostructures in the aerospace business.

About Nikkiso Clean Energy & Industrial Gases Group

The Nikkiso Clean Energy & Industrial Gases Group is a leading provider of cryogenic equipment, technologies and applications for clean energy and industrial gas market segments. The Group employs more than 1,600 people in 22 countries and is headed by Cryogenic Industries, Inc. in Southern California, U.S., which is a wholly owned subsidiary of Nikkiso Co., Ltd. (TSE: 6376).

Media contact
Lisa Adams
+1 405 492 1689

GlobeNewswire Distribution ID 9153273

Posted on

Canada Under Investigation by UN Partner for Anti-Black Discrimination

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) — In a landmark decision, the international body that hands out human rights accreditations has concluded that there is enough basis to review Canada’s “A” status – an unprecedented move that puts it among the ranks of countries like Russia, Iraq, and Venezuela.

The Global Alliance of National Human Rights Institutions (GANHRI) — a United Nations partner — has launched a “Special Review” of the accreditation of the Canadian Human Rights Commission (CHRC). This comes as the result of a complaint by a coalition of Canadian human rights organizations, which submitted federal findings of anti-Black discrimination at the Canadian Human Rights Commission as evidence.

Despite admitting to human rights violations, the Canadian government is currently vying for a seat in the United Nations Human Rights Council from 2028-2030, with a vote happening in 2026.

“With this international review, the Canadian government is now on notice,” says Nicholas Marcus Thompson, with the Black Class Action Secretariat, the coalition lead. “It cannot claim to be a global leader in human rights, while discriminating against its own at home.”

If the international body finds there are grounds to downgrade the CHRC to “B” status, for the first time ever, it will no longer have independent participation rights at the UN Human Rights Council, its subsidiary bodies, and some General Assembly bodies and mechanisms. Further, it will lose the right to vote and hold governance positions at GANHRI.

“The implications of this decision are very serious as Canada has never had its status reviewed in its more than 30 years as a GANHRI member,” says Ketty Nivyabandi, Secretary General for Amnesty International Canada. “We urge the Canadian government and the Commission to take all necessary measures to guarantee the integrity of the Commission and its critical role for Canadians.”

In line with the International Decade for People of African Descent, the coalition is calling for:

  • JUSTICE: Creating a properly funded direct-access model to the Canadian Human Rights Tribunal (removing CHRC’s role as a gatekeeper with the power to dismiss claims before they reach the Tribunal)
  • RECOGNITION: Expediting Employment Equity Act amendments to include Black people as an employment equity group.
  • DEVELOPMENT: Appointing a Black Equity Commissioner to address discrimination in the public service.

WATCH PRESS CONFERENCE AND ACCESS PHOTOS HERE: https://www.bcas-srcn.org/post/chrc-under-special-review-for-discrimination

MEDIA CONTACT: Ginella Massa, Massa Media & Comms | info@massamedia.ca

BACKGROUND INFO:

On Feb 26, 2024, a coalition of human rights organizations submitted a complaint to the Global Alliance of National Human Rights Institutions (GANHRI).

The coalition consists of: The Black Class Action Secretariat (BCAS), the Public Service Alliance of Canada (PSAC), the National Union of Public and General Employees (NUPGE), the Canadian Black Nurses Alliance (CBNA), The Enchanté Network, the Red Coalition, the Federation of Black Canadians (FBC), 613-819 Black Hub, the Black Canadians Civil Society Coalition (BCCSC) and The Canadian Association of Professional Employees (CAPE)

The group provided as evidence: the findings of the Treasury Board of Canada Secretariat’s and the Senate Human Rights Committee’s findings of anti-black discrimination.

The complaint highlighted: violations to international human rights laws, and the Paris Principles, internationally agreed upon minimum standards which member human rights institutions are required to adhere to.

The Global Alliance of National Human Rights Institutions (GANHRI) is one of the largest human rights networks worldwide, representing more than 110 National Human rights institutions. It is a recognised, and trusted partner, of the United Nations. GANHRI’s Sub-Committee on Accreditation is responsible for reviewing and accrediting national human rights institutions in compliance with the Paris Principles. The SCA met March 26-28 and published its report and recommendations on June 7, 2024. It decided to initiate a review of Iraq and Canada.

Canada has been a member of GAHNRI since its inception in 1993, through the Canadian Human Rights Commission. Its last accreditation review period was from 2016-2022, with its next review slated for 2027. This unprecedented “Special Review”, which Canada has never been subject to in its member history, will investigate the five year period preceding its most recent “A” status accreditation in 2022.

GANHRI members are reviewed every 5 years. As of December 2023, GANHRI is composed of 120 members: 88 “A” status accredited NHRIs and 32 “B” status accredited NHRIs.

There are currently two levels of accreditation:
Status “A” (Fully compliant with the Paris Principles): Institutions participate fully in the international and regional work and meetings of national institutions as voting members, and they can hold office in the Bureau of the International Coordinating Committee or any sub-committee the Bureau establishes. They are also able to participate in sessions of the Human Rights Council and take the floor under any agenda item, submit documentation and take up separate seating.
Status “B” (Partially compliant with the Paris Principles): Institutions may participate as observers in the international and regional meetings of the national human rights institutions. They cannot vote or hold office with the Bureau or its sub-committees. They are not given NHRIs badges, nor may they take the floor under agenda items and submit documentation to the Human Rights Council.

Countries that have previously been under Special Review: Burundi, Madagascar, Nigeria, Chile, Ecuador, Honduras, Mexico, Indonesia, Jordan, Nepal, Great Britain, Panama, Venezuela, Myanmar, Sri Lanka, Afghanistan, Russia, Iraq.

Special Review Process and timeline: GANHRI will conduct Canada’s Special Review in the fall of 2024, with a decision in the ensuing months. It will examine the five year period from 2016-2022 that led to its most recent “A” status accreditation. If Canada is downgraded to “B” status, it will no longer have independent participation rights at the UN Human Rights Council, its subsidiary bodies and some General Assembly bodies and mechanisms, and will lose the right to vote and hold governance positions at GANHRI.

ADDITIONAL FILES:

VIDEO: GANRHI Meeting
https://www.instagram.com/reel/CzjpWKcJGhX/?igsh=ajk2dHlmcWVnZmd6

MAP: Countries subjected to Special Review
https://static.wixstatic.com/media/8e4f35_458bc54c3f894c6690c810cb81e9b376~mv2.jpg

MAP: GANHRI countries with A/B certifications
https://www.ohchr.org/sites/default/files/Documents/Issues/HRIndicators/NHRI_map.pdf

GlobeNewswire Distribution ID 9153017